Lilly Supports RNA R&D Push With $700m Investment In Institute For Genetic Medicine

Boston Research Team Will Double In Five Years

 
• By Mandy Jackson

The big pharma has a gene therapy R&D site in New York from its Prevail Therapeutics buy; the RNA-focused Boston site also will conduct drug delivery research benefitting programs at both locations.

DNA genetic code biotechnology background science medicine 3D
Nucleic acid medicines is a big focus area for Lilly's R&D organization • Source: Alamy

More from R&D

More from Scrip